ArticleThe Journal of infectious diseases2018
The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease.
Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Transient receptor potential channels inChannels (Austin, Tex.) · 2026Review
- TRPV4-mediated calcium influx contributes temperature-dependent SARS-CoV-2 replication.PLoS pathogens · 2026Article
- Temporal transcriptomics identifies early-response and infection-condition-specific modules guiding host-directed anti-EBOV therapeutics.Microbiology spectrum · 2026Article
- Review
- The crucial role of intercellular calcium wave propagation triggered by influenza A virus in promoting infection.Cell communication and signaling : CCS · 2025Article
- Suppression of Metastatic Ovarian Cancer Cells by Bepridil, a Calcium Channel Blocker.Life (Basel, Switzerland) · 2023Article
- Treatment with Ad5-Porcine Interferon-α Attenuates Ebolavirus Disease in Pigs.Pathogens (Basel, Switzerland) · 2022Article
- Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay.ACS central science · 2022Article
- Dihydropyridine-derived calcium channel blocker as a promising anti-hantavirus entry inhibitor.Frontiers in pharmacology · 2022Article
- Heterogeneous network propagation with forward similarity integration to enhance drug-target association prediction.PeerJ. Computer science · 2022Article
- The downregulation of NCXs is positively correlated with the prognosis of stage II-IV colon cancer.World journal of surgical oncology · 2021Article
- Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo.Microorganisms · 2021Article
- Bepridil is potent against SARS-CoV-2 in vitro.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.Advances and applications in bioinformatics and chemistry : AABC · 2021Article
- Screening of a Small Molecule Compound Library Identifies Toosendanin as an Inhibitor Against Bunyavirus and SARS-CoV-2.Frontiers in pharmacology · 2021Article
- Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension.Cell discovery · 2020Article
- Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection.Frontiers in microbiology · 2020Review
- Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality.Cell research · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
No therapeutics are approved for the treatment of filovirus infections. Bepridil, a calcium channel blocker developed for treating angina, was identified as a potent inhibitor of filoviruses in vitro, including Ebola and Marburg viruses, and Ebola virus in vivo. We evaluated the efficacy of bepridil in a lethal mouse model of Marburg virus disease. A dose of 12 mg/kg bepridil once or twice daily resulted in 80% or 90% survival, respectively. These data confirm bepridil's broad-spectrum anti-filovirus activity warranting further investigation of bepridil, or improved compounds with a similar mechanism, as a pan-filovirus therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.